On October 22, 2026 Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, reported that clinical data from a Phase 2 study of BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an anti-PD-1 monoclonal antibody in First Line NSCLC, will be presented at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will highlight findings from the combination regimen in patients with first-line non-small cell lung cancer (NSCLC), including an evaluation of its antitumor activity and safety profile. The study reflects Bio-Thera’s continued commitment to advancing innovative antibody-based therapies for patients with significant unmet medical needs.
Lung cancer remains a leading cause of cancer-related mortality worldwide, and NSCLC accounts for the majority of lung cancer cases. Despite advances in immunotherapy and combination treatment approaches, new therapeutic strategies remain an important area of research for patients with advanced NSCLC.
BAT8008 is a TROP2-targeted ADC designed to deliver an exatecan payload, a cytotoxic TOP1 inhibitor, to tumor cells expressing TROP2. BAT1308 is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), an immune checkpoint involved in regulating antitumor immune responses. The combination is being investigated for its potential to integrate targeted cytotoxic activity with immune checkpoint inhibition.
Presentation Details
Congress: 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress
Presentation: First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter Phase 2 study
Presentation format: Rapid Oral 1: NSCLC, metastatic
Abstract number: 2631RO
Date: Saturday, October 24, 2026
Time: 8:30–10:00 a.m. CEST (session window)
Location: Almeria Auditorium, Hall 9
The presentation will provide further insight into the clinical development of this investigational combination. The full data will be presented at the ESMO (Free ESMO Whitepaper) 2026 Congress.
(Press release, BioThera Solutions, OCT 22, 2026, View Source [SID1234673684])